Prevention of Rh-haemolytic Disease: Final Results of the "High-risk" Clinical Trial: A COMBINED STUDY FROM CENTRES IN ENGLAND AND BALTIMORE

Publisher Website
Google Scholar
Abstract
The final results are reported of a trial of about 1,000 μg of anti-D gammaglobulin given intramuscularly to a selected high-risk group of Rh-negative primiparae just delivered of an ABO-compatible Rh-positive baby, the aim being to prevent them becoming immunized to Rh. Six months after delivery only 1 out of 173 treated mothers had been immunized as against 38 out of 176 controls. The crucial test of the prophylactic therapy depends on the presence or otherwise of anti-D at the end of a second Rh-positive pregnancy. Of 86 treated mothers two had antibodies at this time compared with 20 out of 65 controls. The results show a high degree of protection in this group of mothers.

This publication has 0 references indexed in Scilit: